BNT162b4 (T-Cell Boosting COVID Vaccine)
COVID-19 (Enhanced T-cell response)
SponsorBioNTech
1,800Enrollment Target
45Trial Sites
3Countries
November 2026Est. Completion
About This Trial
Novel vaccine component designed to enhance T-cell immunity for longer-lasting protection regardless of variants.
Primary Endpoints
- T-cell response magnitude
- Duration of cellular immunity
Latest Update
February 2026
Phase 1 showed 4-fold increase in virus-specific T-cells persisting at 6 months. Moving to expanded Phase 2.
Lead Investigators
DU
Dr. Ugur SahinCEO & Co-founder, BioNTech
DÖ
Dr. Özlem TüreciCMO & Co-founder, BioNTech